Cargando…
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactiv...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275151/ https://www.ncbi.nlm.nih.gov/pubmed/32778225 http://dx.doi.org/10.1016/j.cell.2020.06.008 |
| _version_ | 1783542725974425600 |
|---|---|
| author | Wang, Hui Zhang, Yuntao Huang, Baoying Deng, Wei Quan, Yaru Wang, Wenling Xu, Wenbo Zhao, Yuxiu Li, Na Zhang, Jin Liang, Hongyang Bao, Linlin Xu, Yanfeng Ding, Ling Zhou, Weimin Gao, Hong Liu, Jiangning Niu, Peihua Zhao, Li Zhen, Wei Fu, Hui Yu, Shouzhi Zhang, Zhengli Xu, Guangxue Li, Changgui Lou, Zhiyong Xu, Miao Qin, Chuan Wu, Guizhen Gao, George Fu Tan, Wenjie Yang, Xiaoming |
| author_facet | Wang, Hui Zhang, Yuntao Huang, Baoying Deng, Wei Quan, Yaru Wang, Wenling Xu, Wenbo Zhao, Yuxiu Li, Na Zhang, Jin Liang, Hongyang Bao, Linlin Xu, Yanfeng Ding, Ling Zhou, Weimin Gao, Hong Liu, Jiangning Niu, Peihua Zhao, Li Zhen, Wei Fu, Hui Yu, Shouzhi Zhang, Zhengli Xu, Guangxue Li, Changgui Lou, Zhiyong Xu, Miao Qin, Chuan Wu, Guizhen Gao, George Fu Tan, Wenjie Yang, Xiaoming |
| author_sort | Wang, Hui |
| collection | PubMed |
| description | The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial. |
| format | Online Article Text |
| id | pubmed-7275151 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72751512020-06-08 Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 Wang, Hui Zhang, Yuntao Huang, Baoying Deng, Wei Quan, Yaru Wang, Wenling Xu, Wenbo Zhao, Yuxiu Li, Na Zhang, Jin Liang, Hongyang Bao, Linlin Xu, Yanfeng Ding, Ling Zhou, Weimin Gao, Hong Liu, Jiangning Niu, Peihua Zhao, Li Zhen, Wei Fu, Hui Yu, Shouzhi Zhang, Zhengli Xu, Guangxue Li, Changgui Lou, Zhiyong Xu, Miao Qin, Chuan Wu, Guizhen Gao, George Fu Tan, Wenjie Yang, Xiaoming Cell Article The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial. Elsevier Inc. 2020-08-06 2020-06-06 /pmc/articles/PMC7275151/ /pubmed/32778225 http://dx.doi.org/10.1016/j.cell.2020.06.008 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Wang, Hui Zhang, Yuntao Huang, Baoying Deng, Wei Quan, Yaru Wang, Wenling Xu, Wenbo Zhao, Yuxiu Li, Na Zhang, Jin Liang, Hongyang Bao, Linlin Xu, Yanfeng Ding, Ling Zhou, Weimin Gao, Hong Liu, Jiangning Niu, Peihua Zhao, Li Zhen, Wei Fu, Hui Yu, Shouzhi Zhang, Zhengli Xu, Guangxue Li, Changgui Lou, Zhiyong Xu, Miao Qin, Chuan Wu, Guizhen Gao, George Fu Tan, Wenjie Yang, Xiaoming Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 |
| title | Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 |
| title_full | Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 |
| title_fullStr | Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 |
| title_full_unstemmed | Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 |
| title_short | Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 |
| title_sort | development of an inactivated vaccine candidate, bbibp-corv, with potent protection against sars-cov-2 |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275151/ https://www.ncbi.nlm.nih.gov/pubmed/32778225 http://dx.doi.org/10.1016/j.cell.2020.06.008 |
| work_keys_str_mv | AT wanghui developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT zhangyuntao developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT huangbaoying developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT dengwei developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT quanyaru developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT wangwenling developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT xuwenbo developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT zhaoyuxiu developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT lina developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT zhangjin developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT lianghongyang developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT baolinlin developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT xuyanfeng developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT dingling developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT zhouweimin developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT gaohong developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT liujiangning developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT niupeihua developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT zhaoli developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT zhenwei developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT fuhui developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT yushouzhi developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT zhangzhengli developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT xuguangxue developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT lichanggui developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT louzhiyong developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT xumiao developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT qinchuan developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT wuguizhen developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT gaogeorgefu developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT tanwenjie developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 AT yangxiaoming developmentofaninactivatedvaccinecandidatebbibpcorvwithpotentprotectionagainstsarscov2 |